LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Cerrado

SectorSanidad

13.59 0.59

Resumen

Variación precio

24h

Actual

Mínimo

13.56

Máximo

13.59

Métricas clave

By Trading Economics

Ingresos

-9.7B

2.2B

Ventas

-11B

76B

P/B

Media del Sector

26.154

49.701

Rentabilidad por dividendo

0.67

Margen de beneficios

2.928

Empleados

27,811

EBITDA

-13B

6.1B

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.67%

2.39%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

384M

11B

Apertura anterior

13

Cierre anterior

13.59

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

159 / 345 Clasificación en Healthcare

Dr Reddy's Laboratories Ltd-ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 oct 2025, 14:47 UTC

Principales Movimientos del Mercado

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12 may 2026, 12:16 UTC

Ganancias

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12 may 2026, 12:16 UTC

Ganancias

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12 may 2026, 12:08 UTC

Ganancias

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12 may 2026, 12:06 UTC

Ganancias

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12 may 2026, 12:02 UTC

Ganancias

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12 may 2026, 12:01 UTC

Ganancias

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23 jul 2025, 17:49 UTC

Ganancias

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23 jul 2025, 17:48 UTC

Ganancias

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23 jul 2025, 17:48 UTC

Ganancias

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Comparación entre iguales

Cambio de precio

Dr Reddy's Laboratories Ltd-ADR previsión

Consenso

By TipRanks

Vender

1 ratings

0

Comprar

0

Mantener

1

Vender

Sentimiento

By Acuity

159 / 345 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat